8月15日，五洲医疗今日收盘40.33元，下跌1.99%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到76.78倍，总市值27.42亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均56.58倍，行业中值39.97倍，五洲医疗排 名第97位。 资金流向方面，8月15日，五洲医疗主力资金净流出112.57万元，近5日总体呈流入状态，5日共流入 366.58万元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13五洲医疗76.7868.613.5727.42亿行业平均 56.5852.305.00119.53亿行业中值39.9739.072.9157.03亿1九安医疗11.3611.490.89191.70亿2英科医疗 15.6416.861.39247.04亿3山东药玻16.2816.331.87154.02亿4新华医疗16.6315.411.36106.59亿5奥美医疗 17.1216.781.7661.87亿6振德医疗17.3816.381.1163.10亿7九强生物17.7016.462.1787.65亿8康德莱 18.0418.051.4938.87亿9维力医疗18 ...

8月11日，五洲医疗今日收盘42.56元，上涨1.19%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到81.02倍，创480天以来新低，总市值28.94亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均56.56倍，行业中值39.76倍，五洲医疗排 名第101位。 股东方面，截至2025年7月31日，五洲医疗股东户数7255户，较上次增加848户，户均持股市值35.28万 元，户均持股数量2.76万股。 安徽宏宇五洲医疗器械股份有限公司的主营业务是一次性使用无菌输注类医疗器械的研发、制造和销 售，以及其他诊断、护理等相关医疗用品的集成供应。公司的主要产品是注射器、安全型注射器、胰岛 素注射器、配药注射器、输液器、输血器、注射针、静脉输液针、采血针、胰岛素注射笔用针头、安全 注射针、安全采血针、血压表、面罩。 最新一期业绩显示，2025年一季报，公司实现营业收入1.04亿元，同比15.59%；净利润563.45万元，同 比-43.00%，销售毛利率14.62%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13五洲医疗81.0272.413.7728.94亿行业平均 56. ...

Core Viewpoint - Wuzhou Medical's stock closed at 40.7 yuan on August 1, with a PE ratio of 77.48, marking a 473-day low, and a total market value of 2.768 billion yuan [1] Company Summary - Wuzhou Medical specializes in the research, manufacturing, and sales of disposable sterile infusion medical devices, along with other diagnostic and nursing supplies [1] - The company's main products include syringes, safety syringes, insulin syringes, infusion sets, blood transfusion sets, and various types of needles [1] - For Q1 2025, Wuzhou Medical reported revenue of 104 million yuan, a year-on-year increase of 15.59%, and a net profit of 5.6345 million yuan, reflecting a year-on-year decrease of 43.00% with a gross margin of 14.62% [1] Industry Summary - The average PE ratio for the medical device industry is 53.65, with a median of 37.22, placing Wuzhou Medical at the 97th position in the industry ranking [1] - The industry average market value is 11.474 billion yuan, while the median is 5.530 billion yuan [2] - Other companies in the industry have significantly lower PE ratios, with the lowest being 11.01 for Jiuan Medical and the highest being 20.06 for Antu Biology [2]

Core Viewpoint - Wuzhou Medical's stock closed at 38.6 yuan on July 28, with a 3.90% increase, and a rolling PE ratio of 73.48, marking a new low in 14 days, with a total market value of 2.625 billion yuan [1] Group 1: Company Performance - The company reported a revenue of 104 million yuan in Q1 2025, representing a year-on-year increase of 15.59% [1] - Net profit for the same period was 5.6345 million yuan, showing a year-on-year decrease of 43.00% [1] - The sales gross margin stood at 14.62% [1] Group 2: Industry Comparison - The average PE ratio for the medical device industry is 55.28, while the median is 38.06, placing Wuzhou Medical at the 96th position in the industry ranking [1][2] - The static PE ratio for Wuzhou Medical is 65.67, and the price-to-book ratio is 3.42 [2] - Other companies in the industry have varying PE ratios, with the lowest being 11.01 for Jiuan Medical and the highest being 20.05 for Sanxin Medical [2] Group 3: Capital Flow - On July 28, Wuzhou Medical experienced a net outflow of 1.549 million yuan in principal funds, although the overall trend over the past five days showed a net inflow of 12.1206 million yuan [1]

Company Overview - Wuzhou Medical's closing price on July 16 was 35.05 yuan, down 2.37%, with a rolling PE ratio of 66.73 times and a total market value of 2.383 billion yuan [1] - The company ranks 94th in the medical device industry, which has an average PE ratio of 51.87 times and a median of 37.48 times [1] Shareholder Information - As of June 30, 2025, Wuzhou Medical had 6,407 shareholders, an increase of 102 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Business Operations - Wuzhou Medical specializes in the research, development, manufacturing, and sales of disposable sterile infusion medical devices, as well as integrated supply of other diagnostic and nursing medical products [1] - Key products include syringes, safety syringes, insulin syringes, infusion sets, blood transfusion sets, and various types of needles and medical masks [1] Financial Performance - In the first quarter of 2025, Wuzhou Medical reported revenue of 104 million yuan, a year-on-year increase of 15.59%, while net profit was 5.6345 million yuan, reflecting a year-on-year decrease of 43.00%, with a gross profit margin of 14.62% [1]

Company Overview - Wuzhou Medical's closing price on July 10 was 37.26 yuan, down 5.43%, with a rolling PE ratio of 70.93 times and a total market value of 2.534 billion yuan [1] - The company ranks 95th in the medical device industry, which has an average PE ratio of 51.40 times and a median of 37.27 times [1] Shareholder Information - As of June 30, 2025, Wuzhou Medical had 6,407 shareholders, an increase of 102 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Business Operations - Wuzhou Medical specializes in the research, manufacturing, and sales of disposable sterile infusion medical devices, along with integrated supply of other diagnostic and nursing medical products [1] - Key products include syringes, safety syringes, insulin syringes, infusion sets, blood transfusion sets, and various types of needles [1] Financial Performance - In the first quarter of 2025, the company reported revenue of 104 million yuan, a year-on-year increase of 15.59%, while net profit was 5.6345 million yuan, reflecting a year-on-year decrease of 43.00%, with a gross profit margin of 14.62% [1]

7月7日，五洲医疗今日收盘38.6元，上涨19.99%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到73.48倍，创420天以来新低，总市值26.25亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均51.42倍，行业中值37.44倍，五洲医疗排 名第98位。 截至2025年一季报，共有3家机构持仓五洲医疗，其中基金2家、QFII1家，合计持股数29.38万股，持股 市值0.08亿元。 安徽宏宇五洲医疗器械股份有限公司的主营业务是一次性使用无菌输注类医疗器械的研发、制造和销 售，以及其他诊断、护理等相关医疗用品的集成供应。公司的主要产品是注射器、安全型注射器、胰岛 素注射器、配药注射器、输液器、输血器、注射针、静脉输液针、采血针、胰岛素注射笔用针头、安全 注射针、安全采血针、血压表、面罩。 最新一期业绩显示，2025年一季报，公司实现营业收入1.04亿元，同比15.59%；净利润563.45万元，同 比-43.00%，销售毛利率14.62%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13五洲医疗73.4865.673.4226.25亿行业平均 51.4249.164. ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Wuzhou Medical, which closed at 28.82 yuan, marking a 2.38% increase, with a rolling PE ratio of 54.87, the lowest in 95 days, and a total market capitalization of 1.96 billion yuan [1] - Wuzhou Medical ranks 89th in the medical device industry based on PE ratio, with the industry average at 49.84 and the median at 36.59 [1][2] - As of the first quarter of 2025, three institutions hold shares in Wuzhou Medical, with a total of 293,800 shares valued at 0.08 million yuan [1] Group 2 - Wuzhou Medical specializes in the research, manufacturing, and sales of disposable sterile infusion medical devices, along with other diagnostic and nursing supplies [1] - The company's main products include syringes, safety syringes, insulin syringes, infusion sets, blood transfusion sets, and various types of needles [1] - In the latest financial report for the first quarter of 2025, Wuzhou Medical reported revenue of 1.04 million yuan, a year-on-year increase of 15.59%, while net profit was 563,450 yuan, reflecting a year-on-year decrease of 43.00%, with a gross profit margin of 14.62% [1]